

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED**

**精優藥業控股有限公司\***

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 00858)**

### **PROPOSED APPOINTMENT OF AUDITOR**

This announcement is made by Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Reference is made to the Company’s announcement dated 12 August 2024 in relation to, among others, the retirement of Elite Partners CPA Limited (“**Elite Partners**”) as the auditor of the Company upon expiration of its term of office at the conclusion of the annual general meeting of the Company held on 23 August 2024.

### **PROPOSED APPOINTMENT OF AUDITOR**

The board of directors of the Company (the “**Board**”) hereby announces that, with the recommendation of the audit committee of the Company (the “**Audit Committee**”), the Board proposed to appoint SFAI (HK) CPA Limited (“**SFAI Hong Kong**”) as the new auditor of the Company to fill the vacancy arising from the retirement of Elite Partners and the term of office of the new auditor will expire until the conclusion of the next annual general meeting of the Company (the “**Proposed Appointment**”). The Proposed Appointment is still subject to the consideration and approval at the special general meeting of the Company (the “**SGM**”), and will take effect from the date of approval at the SGM.

The Audit Committee has considered a number of factors when evaluating the appointment of SFAI Hong Kong as the new auditor of the Company, including but not limited to (i) the audit proposal of SFAI Hong Kong; (ii) SFAI Hong Kong’s experience, knowledge and technical competence in handling audit work for companies listed on the Stock Exchange; (iii) SFAI Hong Kong’s independence from the Group and objectivity; (iv) SFAI Hong Kong’s resources and capabilities; and (v) the guidelines issued by the Accounting and Financial Reporting Council. Based on the above, the Board and the Audit Committee have evaluated and are of the view that SFAI Hong Kong is independent, eligible, capable and suitable to act as the auditor of the Company.

## **THE SGM**

The SGM will be convened and held for the purpose of considering and, if thought fit, approving the Proposed Appointment. A circular containing further information of the Proposed Appointment together with the notice of SGM will be published as soon as practicable.

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 7 March 2025

*As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Dr. Guo Yi, and the independent non-executive directors are Mr. Fang Lin Hu, Ms. Jin Song and Dr. Zeng Li.*

\* *For identification purpose only*